Transit Scientific Announces the Close of Its Series A financing Round

February 3, 2021

Transit Scientific today announced the close of its Series A financing round. The round was led by a large multinational investor and joined by previous seed investors.

Transit Scientific achieved FDA clearances and multi-center, multi-user, safe-patient-use of its XO Score angioplasty scoring-cutting platform and separate XO Cross 0.014″ and 0.035″ microcatheter platform in late 2020.

“XO Score successfully dilated multiple lesions that were resistant to standard or high-pressure balloon angioplasty during our 1st patient uses in hemodialysis fistulas,” said Jeffrey Hoggard MD, of the Raleigh Access Center in Raleigh, North Carolina, USA. “It was particularly beneficial to be able to deploy the XO Score device with a standard PTA balloon in the juxta-anastomotic position and dilate the lesion at low and controlled inflation pressure.”

The XO Score is a novel sheath that converts regular angioplasty balloons into vessel prep scoring and cutting systems. The device is indicated for treatment of peripheral vascular stenosis including hemodialysis fistulas and grafts.

XO Score’s 22 individual scoring & cutting struts rotate 90 degrees to score & cut upon balloon inflation and then rotate 90 degrees back upon balloon deflation to facilitate balloon re-wrap. The technology also allows for infusion at the site of treatment.

“The XO Cross 014, 018, and 035 microcatheter platform adds new torque, pushability and catheter control,” said Richard Saxon, MD, FSIR of the Tri-City Medical Center in Oceanside, CA, USA  “We have used an .014 XO Cross to redirect the guidewire intraluminally while crossing a tibial artery CTO. This would have been very difficult to achieve with other available technology.”

The XO Cross is a non-tapered exoskeleton based micro-catheter technology designed to improve torque response, trackability, and control.

“We are grateful to have smart value-added investors,” said Greg Method, president and chief executive officer of Transit Scientific. “Our team puts patients first and achieved a great deal in 2020 including FDA clearances and, most importantly, safe-patient-uses in a variety of challenging procedures with cardiologists, interventional radiologists, nephrologists, and vascular surgeons at different locations.”

Transit Scientific is a private company that designs, develops, and commercializes medical devices including the FDA-cleared XO ScoreÒ scoring sheath and  XO CrossÒ microcatheters.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version